{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T01:13:14Z","timestamp":1785546794640,"version":"3.56.0"},"reference-count":32,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T00:00:00Z","timestamp":1707955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Hosp Pharm"],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:p>\n                    <jats:bold>Background and Objective:<\/jats:bold>\n                    Olanzapine (OLZ) containing regimens are approved in adults for chemotherapy-induced nausea and vomiting (CINV) receiving highly emetogenic chemotherapy (HEC) or moderately emetogenic chemotherapy (MEC), and the same has not been approved in the pediatric population. In order to generate data regarding the efficacy and safety of OLZ as an adjunct to the standard of care (SoC) for CINV in pediatric patients receiving HEC\/MEC, the review authors performed this systematic review and meta-analysis.\n                    <jats:bold>Methods:<\/jats:bold>\n                    A systematic literature search was performed through the databases Cochrane Library, Pub Med, and clinicaltrials.gov, from inception to September 2023, using keywords: \u201cchemotherapy\u201d and \u201colanzapine,\u201d \u201cnausea\u201d and \u201cvomiting.\u201d Randomized clinical trials published in English that analyzed the efficacy and safety of olanzapine as an adjunct to SoC were included. The essential outcomes included in this study were the proportion of patients with no emesis in the acute and delayed phase, patients with no nausea in the acute and delayed phase, the proportion of patients requiring rescue medication, and the proportion of patients with reduced CNS arousal.\n                    <jats:bold>Results:<\/jats:bold>\n                    In the OLZ group, a greater number of patients had no emesis both in the acute and delayed phase (RR\u2009=\u20091.22; 95% CI\u2009=\u20091.09-1.37;\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2009=\u2009.0004); and (RR\u2009=\u20091.23; 95% CI\u2009=\u20090.92-1.63;\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2009=\u2009.16) respectively. Similarly, a higher number of patients showed no nausea both in the acute and delayed phase (RR\u2009=\u20091.08; 95% CI\u2009=\u20090.78-1.48;\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2009=\u2009.66) and (RR\u2009=\u20091.12; 95% CI\u2009=\u20090.79-1.61;\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2009=\u2009.52) respectively. The use of rescue medication was significantly less in the OLZ group (RR\u2009=\u20090.62; 95% CI\u2009=\u20090.42-0.91;\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2009=\u2009.01). More patients experienced reduced CNS arousal in the OLZ group (RR\u2009=\u20092.97; 95% CI\u2009=\u20092.02-4.38;\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2009&lt;\u2009.0001).\n                    <jats:bold>Conclusions:<\/jats:bold>\n                    Olanzapine as an adjunct to the SoC may be effective in acute emesis, which may also reduce the use of rescue medication. Reduced CNS alertness was the significant adverse effect observed. For other endpoints, more studies are required to substantiate its role in CINV.\n                  <\/jats:p>","DOI":"10.1177\/00185787241231739","type":"journal-article","created":{"date-parts":[[2024,2,16]],"date-time":"2024-02-16T02:00:36Z","timestamp":1708048836000},"page":"415-426","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":4,"title":["Trial Sequential Analysis and Meta-Analysis of Olanzapine in Pediatric Patients for Chemotherapy-Induced Nausea and Vomiting (CINV)"],"prefix":"10.1177","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6720-2756","authenticated-orcid":false,"given":"Alok","family":"Singh","sequence":"first","affiliation":[{"name":"AIIMS Raipur, Raipur, CT, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhyuti","family":"Gupta","sequence":"additional","affiliation":[{"name":"AIIMS Raipur, Raipur, CT, India"},{"name":"Department of Pharmacology, Teerthanker Mahaveer Medical College and Research Centre, Moradabad, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pankaj Kumar","family":"Kannauje","sequence":"additional","affiliation":[{"name":"AIIMS Raipur, Raipur, CT, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit Kumar","family":"Agrawal","sequence":"additional","affiliation":[{"name":"AIIMS Raipur, Raipur, CT, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2024,2,15]]},"reference":[{"key":"e_1_3_3_2_2","unstructured":"Childhood cancer. Accessed October 27 2023. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/cancer-in-children"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12906-022-03537-w"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13312-023-2931-0"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.795664"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.27488"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40272-017-0228-2"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000032116"},{"key":"e_1_3_3_9_2","article-title":"Chemotherapy-induced nausea and vomiting: pathogenesis, recommendations, and new trends","volume":"26","author":"Gupta K","year":"2021","unstructured":"Gupta K, Walton R, Kataria SP. Chemotherapy-induced nausea and vomiting: pathogenesis, recommendations, and new trends. Cancer Treat Res Commun. 2021;26:100278.","journal-title":"Cancer Treat Res Commun"},{"key":"e_1_3_3_10_2","unstructured":"National Cancer Institute. Nausea and vomiting related to cancer treatment (PDQ). Accessed 31 October 2023. https:\/\/www.cancer.gov\/about-cancer\/treatment\/side-effects\/nausea\/nausea-hp-pdq#_590"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-019-0840-0"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-022-06818-9"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.30001"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1200\/JGO.17.00216"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1186\/2046-4053-4-1"},{"key":"e_1_3_3_16_2","author":"Higgins JPT","unstructured":"Higgins JPT, Savovi\u0107 J, Page MJ, et al. Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins JPT, Thomas J, Chandler J, et al. (eds) Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated August 2023). Cochrane, 2023. Accessed October 27, 2023. www.training.cochrane.org\/handbook","journal-title":"Cochrane Handbook for Systematic Reviews of Interventions version 6.4"},{"key":"e_1_3_3_17_2","article-title":"Rob 2: A revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JAC","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, et al. Rob 2: A revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.","journal-title":"BMJ"},{"key":"e_1_3_3_18_2","author":"Sch\u00fcnemann HJ","unstructured":"Sch\u00fcnemann HJ, Higgins JPT, Vist GE, et al. Chapter 14: Completing \u2018Summary of findings\u2019 tables and grading the certainty of the evidence. In: Higgins JPT, Thomas J, Chandler J, et al. (eds) Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated August 2023). Cochrane, 2023. Accessed October 27, 2023. https:\/\/www.training.cochrane.org\/handbook","journal-title":"Cochrane Handbook for Systematic Reviews of Interventions version 6.4"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-021-01867-6"},{"key":"e_1_3_3_20_2","first-page":"1","volume-title":"User Manual for Trial Sequential Analysis (TSA) [Pdf]","author":"Thorlund K","unstructured":"Thorlund K, Engstr\u00f8m J, Wetterslev J, et al. (eds.). User Manual for Trial Sequential Analysis (TSA) [Pdf]. 2nd ed. Copenhagen Trial Unit; 2017:1-119. Accessed October 27, 2023.\u2009ctu.dk\/tsa.","edition":"2"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000035299"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.28532"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-017-3864-8"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.24287\/1726-1708-2022-21-4-70-82"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.4103\/abr.abr_356_22"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0000000000002408"},{"issue":"1","key":"e_1_3_3_27_2","first-page":"318","article-title":"Efficacy and safety of adding olanzapine to the standard preventive regimen for chemotherapy-induced nausea and vomiting in children: a randomized double-blind controlled trial","volume":"20","author":"Moshayedi M","year":"2021","unstructured":"Moshayedi M, Salehifar E, Karami H, et al. Efficacy and safety of adding olanzapine to the standard preventive regimen for chemotherapy-induced nausea and vomiting in children: a randomized double-blind controlled trial. Iran J Pharm Res. 2021;20(1):318-326.","journal-title":"Iran J Pharm Res"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00871"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01296"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0000000000002737"},{"key":"e_1_3_3_31_2","unstructured":"Highlights of Prescribing Information (ZYPREXA). Accessed November 04 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/020592s062021086s040021253s048lbl.pdf"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1177\/02537176231201326"},{"key":"e_1_3_3_33_2","unstructured":"Deeks JJ Higgins JP Altman DG. Analysing data and undertaking meta-analyses. Accessed November 04 2023. https:\/\/training.cochrane.org\/handbook\/current\/chapter-10"}],"container-title":["Hospital Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/00185787241231739","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/00185787241231739","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/00185787241231739","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T11:03:10Z","timestamp":1784545390000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/00185787241231739"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,15]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["10.1177\/00185787241231739"],"URL":"https:\/\/doi.org\/10.1177\/00185787241231739","relation":{},"ISSN":["0018-5787","1945-1253"],"issn-type":[{"value":"0018-5787","type":"print"},{"value":"1945-1253","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,15]]}}}